479 related articles for article (PubMed ID: 23270807)
21. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
22. [Comparative activity of several antibiotics against Toxoplasma gondii in a mouse model].
Rodríguez-Díaz JC; Martínez-Grueiro MM; Martínez-Fernández AR
Enferm Infecc Microbiol Clin; 1993 Dec; 11(10):543-6. PubMed ID: 8142504
[TBL] [Abstract][Full Text] [Related]
23. Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the Calomys callosus model.
Lopes CD; Silva NM; Ferro EA; Sousa RA; Firminot ML; Bernardes ES; Roque-Barreira MC; Pena JD
J Parasitol; 2009 Aug; 95(4):1005-10. PubMed ID: 20050006
[TBL] [Abstract][Full Text] [Related]
24. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Khan AA; Lambert LH; Remington JS; Araujo FG
Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177
[TBL] [Abstract][Full Text] [Related]
25. Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.
de Oliveira TC; Silva DA; Rostkowska C; Béla SR; Ferro EA; Magalhães PM; Mineo JR
Exp Parasitol; 2009 Jul; 122(3):233-41. PubMed ID: 19389400
[TBL] [Abstract][Full Text] [Related]
26. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Kovacs JA; Allegra CJ; Chabner BA; Swan JC; Drake J; Lunde M; Parrillo JE; Masur H
J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446
[TBL] [Abstract][Full Text] [Related]
27. [New pathogens and mode of action of azithromycin: Toxoplasma gondii].
Derouin F
Pathol Biol (Paris); 1995 Jun; 43(6):561-4. PubMed ID: 8539083
[TBL] [Abstract][Full Text] [Related]
28. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
29. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
30. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.
Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA
Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866
[TBL] [Abstract][Full Text] [Related]
32. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
Chirgwin K; Hafner R; Leport C; Remington J; Andersen J; Bosler EM; Roque C; Rajicic N; McAuliffe V; Morlat P; Jayaweera DT; Vilde JL; Luft BJ
Clin Infect Dis; 2002 May; 34(9):1243-50. PubMed ID: 11941551
[TBL] [Abstract][Full Text] [Related]
34. Lack of therapeutic effect of colchicine on murine toxoplasmosis.
Aguirre-Cruz L; Sotelo J
J Parasitol; 1998 Feb; 84(1):163-4. PubMed ID: 9488356
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis.
Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A
Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693
[TBL] [Abstract][Full Text] [Related]
36. Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study.
Reiter-Owona I; Hlobil H; Enders M; Klarmann-Schulz U; Gruetzmacher B; Rilling V; Hoerauf A; Garweg JG
Eur J Med Res; 2020 Nov; 25(1):59. PubMed ID: 33228795
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Martinez A; Allegra CJ; Kovacs JA
Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
[TBL] [Abstract][Full Text] [Related]
38. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.
Mack DG; McLeod R
Antimicrob Agents Chemother; 1984 Jul; 26(1):26-30. PubMed ID: 6383209
[TBL] [Abstract][Full Text] [Related]
39. Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.
Khan AA; Nasr M; Araujo FG
Antimicrob Agents Chemother; 1998 Sep; 42(9):2284-9. PubMed ID: 9736550
[TBL] [Abstract][Full Text] [Related]
40. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Schoondermark-van de Ven E; Galama J; Vree T; Camps W; Baars I; Eskes T; Meuwissen J; Melchers W
Antimicrob Agents Chemother; 1995 Jan; 39(1):137-44. PubMed ID: 7695295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
